Inclusion Criteria:

- Patients must be 18 to 70 years old, signed ICF;

- At least 4 weeks after previous chemotherapy (6 weeks since nitrosoureas);

- KPS ≥ 60;

- Unilateral, Supratentorial, solitary lesion and not crossing the midline(exclude
patients with little tumors near the resectable tumor even if investigators think
they are single lesions)

- No obvious important organ dysfunction: Blood routine: White blood cell (WBC) ≥
4.0×109/L, Absolute neutrophil count (ANC)≥ 1.5×109/L, Platelets≥ 100×109/L,
Hemoglobin≥ 90 g/L; Hepatic function:Serum total bilirubin ≤1.5 times upper limit of
laboratory normal; Aspartate aminotransferase (AST) and/or Alanine aminotransferase
(ALT)＜2.5 times upper limit of laboratory normal; Renal function:Serum creatinine
≤1.5 times upper limit of laboratory normal;

- Not Pregnant or lactating for women of childbearing potential.

Exclusion Criteria:

- Tumor located at ventricular system, Open ventricle tumor cavity postoperatively;

- Concomitant with other life-threatening diseases and with life expectancy ＜3 months;

- Allergic to nitrosourea drugs;

- With history of intracranial radiotherapy or implant chemotherapy;

- With serious cardiac, pulmonary, hepatic and renal dysfunction, poor glycemic
control;

- Investigators thought unsuitable for enrollment.